Close the Communication Gap with Your Doctor

Think about how involved you want to be. Some patients are very involved in their healthcare from the start, while others might prefer not to ask too many questions or talk too much about their diagnosis or treatment. If you tend to be less involved, consider that taking an active role in getting an accurate diagnosis and making treatment decisions could have a positive effect on your health and quality of life. You can enlist the help of family members, friends, other cancer patients, and patient advocates to support you with provider communications. Remember that you and members of your oncology team are working together to beat blood cancer.

Ask questions. But don’t just ask questions – make sure you take notes in case you forget anything that you might want to remember later. Not sure what to ask? Go to www.lls.org/whattoask to download printable question guides you can take with you on your medical appointments.

Find out what lines of communication are available to you. Are you the type of person that picks up the phone when you have a question or are you more likely to want to send an email? Ask your medical team if they wouldn’t mind you calling or emailing them with additional questions.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap